1. Academic Validation
  2. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor

Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor

  • J Biol Chem. 2010 Jan 1;285(1):723-30. doi: 10.1074/jbc.M109.033829.
Christina Rye Underwood 1 Patrick Garibay Lotte Bjerre Knudsen Sven Hastrup Günther H Peters Rainer Rudolph Steffen Reedtz-Runge
Affiliations

Affiliation

  • 1 Department of GLP-1 and Obesity Biology, Novo Nordisk, 2760 Måløv, Denmark.
Abstract

GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to food intake. Activation of the GLP-1 Receptor potentiates the synthesis and release of Insulin from pancreatic beta-cells in a glucose-dependent manner. The GLP-1 Receptor belongs to class B of the G-protein-coupled receptors, a subfamily characterized by a large N-terminal extracellular ligand binding domain. Exendin-4 and GLP-1 are 50% identical, and exendin-4 is a full agonist with similar affinity and potency for the GLP-1 Receptor. We recently solved the crystal structure of the GLP-1 Receptor extracellular domain in complex with the competitive antagonist exendin-4(9-39). Interestingly, the isolated extracellular domain binds exendin-4 with much higher affinity than the endogenous agonist GLP-1. Here, we have solved the crystal structure of the extracellular domain in complex with GLP-1 to 2.1 Aresolution. The structure shows that important hydrophobic ligand-receptor interactions are conserved in agonist- and antagonist-bound forms of the extracellular domain, but certain residues in the ligand-binding site adopt a GLP-1-specific conformation. GLP-1 is a kinked but continuous alpha-helix from Thr(13) to Val(33) when bound to the extracellular domain. We supplemented the crystal structure with site-directed mutagenesis to link the structural information of the isolated extracellular domain with the binding properties of the full-length receptor. The data support the existence of differences in the binding modes of GLP-1 and exendin-4 on the full-length GLP-1 Receptor.

Figures